BALAXI PHARMACEUTICALS LIMITED has informed the Exchange regarding Outcome of Board Meeting held on May 28, 2026.
BALAXI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Balaxi Pharmaceuticals reported Q4 and FY2026 audited financial results. Standalone revenue grew 32.6% to Rs. 8,085.11 lakhs with PAT up 42.9% to Rs. 514.69 lakhs. However, consolidated revenue declined 7.7% to Rs. 27,017.35 lakhs with PAT dropping sharply to Rs. 141.69 lakhs from Rs. 2,507.02 lakhs in FY2025. The company received manufacturing licence for its Jadcherla formulation plant on May 23, 2026, and is preparing for commercialization of Paracetamol and Piroxicam products. The Board also re-appointed internal auditors and recommended re-appointment of Ms. Akshita Ostwal as Independent Director. Auditors issued unmodified opinions on both standalone and consolidated financials.
Standalone performance shows strong growth, but consolidated results reveal significant profit decline due to losses in overseas subsidiaries. The new manufacturing plant licence is a positive development for future revenue diversification.